Table 1.
Characteristics of the group
| Phacoemulsification | Phacotrabeculectomy | P | |
|---|---|---|---|
| Number | 20 | 20 | P > 0.05 |
| Age | 73.7 ± 1.8 | 72.1 ± 1.9 | P > 0.05 |
| IOP (mmHg) | 13.3 ± 0.8 | 21.5 ± 1.6 | P < 0.05 |
| Creatinine (mg/ml) | 0.82 ± 0.04 | 0.84 ± 0.04 | P < 0.05 |
| eGFR (ml/min/1.73 m2) | 87 ± 6 | 90 ± 5 | P > 0.05 |
| Cup-to-disc ratio | 0.3 ± 0.1 | 0.8 ± 0.2 | P < 0.05 |
| Number of anti-glaucoma drugs | 0 | 3 ± 0.2 | P < 0.05 |
| Mean deviation (visual field) | 0.2 ± 0.5 | 6.2 ± 1.2 | P < 0.05 |
| LOCS III nuclear score | 3 ± 0.3 | 3.2 ± 0.35 | P > 0.05 |
| Diseases related to cardiovascular mortality | |||
| Hypertension | 16 | 14 | P > 0.05 |
| Ischemic heart disease | 5 | 3 | P > 0.05 |
| Diabetes | 4 | 5 | P > 0.05 |
| Classes of anti-glaucoma medication | |||
| Prostaglandins | 0 | 16 | P < 0.05 |
| Beta blockers | 0 | 14 | P < 0.05 |
| Alpha-2 agonists | 0 | 15 | P < 0.05 |
| Anhydrase inhibitors | 0 | 16 | P < 0.05 |
Results are expressed as an absolute number or a mean ± standard error of the mean (SEM)
LOCS III—The lens opacities classification system